We use cookies for a better user experience. Read our Privacy Policy

I Agree

Global Plasma Protease C1-inhibitor Treatment Market to Exhibit 20.0% CAGR over 2017-2025 as Acute HAE Cases Rise Globally

Pharmaceutical |

The vendor landscape of the global market for plasma protease c1-inhibitor treatment market is largely consolidated with a handful of companies collectively accounting for a lion's share in the market and maintaining a tough level of competition, observes Transparency Market Research in a recent report. The company Shire plc. held the dominant spot in the market, thanks to its expansive product portfolio and extensive geographical reach. Other leading companies in the market, including CSL Limited, Pharming Group N.V., and Sanquin are focused on expanding their geographical outreach, product portfolios, and startegic collaborations to establish a stronghold on the market.

According to the report, the global plasma protease c1-inhibitor treatment market will exhibit an impressive 20.0% CAGR from 2017 to 2025. Considering that the numbers hold true, the market is expected to rise from a valuation of US$1.5 bn in 2016 to a revenue opportunity of US$7.9 bn by the end of 2025.

plasma protease c1 inhibitor treatment marketNorth America Takes Lead; to Retain Dominance as HAE and Prophylaxis Cases Rise

Of the key drug classes used in plasma protease C1-inhibitor treatment covered under the report, the segment of C1-inhibitors accounted for the dominant share in the market in 2016. The wide usage of this drug class for the treatment of conditions such as prophylaxis and acute hereditary angioedema (HAE) is likely to keep their demand steady across the globe. Geographically, the global plasma protease c1-inhibitor treatment market acquires a large share of its revenue from sales across the North America region. The regional market presents high demand for plasma protease c1-inhibitor treatment owing to the high number of HAE cases in the U.S.

Rise in Research Efforts Aimed at Development of Novel C1-inhibitor Drug Classes to Bode Well for Market

The rising awareness regarding the available treatment options for HAE is one of the key factors driving the global plasma protease C1-inhibitor treatment market. Other contributing factors include the steadily expanding pipeline of novel drug classes and formulations, thanks to an increase in investment for the research and development of inhibitor drugs, and the rising prevalence of acute HAE and prophylaxis globally. The market is also benefitting from the rising practice of prescribing prophylactic treatment procedure for HAE patients, increased focus on the research related to a new route of administering C1-inhibitor medicines, and increased demand for subcutaneous administration of C1-inhibitor drugs in HAE patient.

Furthermore, the market could also benefit from the increased availability of C1-inhibitor drugs such as Ruconest in emerging economies with vast unmet needs in the area of HAE and prophylaxis treatment. Research efforts underway aimed at the development of bradykinin B2 receptor antagonist for HAE attack treatment is also likely to work in favor of the market.

This review of the global plasma protease C1-inhibitor treatment market is based on a recent market research report by Transparency Market Research, titled “Plasma Protease C1-inhibitor Treatment Market (Drug Class- C1-inhibitors (C1-esterase Inhibitor and Recombinant Inhibitor), Kallikrein Inhibitor (Kalbitor), and Selective Bradykinin B2 Receptor Antagonist (Firazyr); Distribution Channel - Hospital Pharmacies and Independent Pharmacies and Outlets; Dosage Type - Lyophilized and Liquid/Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025.

For the study, the market has been segmented as follows:

  • Global Plasma Protease C1-inhibitors Treatment Market, by Drug Class
    • C1-inhibitors
      • C1-esterase Inhibitor
      • Recombinant Inhibitor
    • Kallikrein Inhibitor (Kalbitor)
    • Selective Bradykinin B2 Receptor Antagonist (Firazyr)|
  • Global Plasma Protease C1-inhibitors Treatment Market, by Dosage Type
    • Liquid/Injectable
    • Lyophilized
  • Global Plasma Protease C1-inhibitors Treatment Market, by Distribution Channel
    • Hospital Pharmacies
    • Independent Pharmacies and Outlets
  • Global Plasma Protease C1-inhibitors Treatment Revenue, By Geography 
    • North America
      • U.S.
      • Canada
    • Europe
      • EU-5 Countries
      • BENELUX Countries
      • Rest of Europe
    • Latin America
      • Argentina
      • Brazil
      • Rest of Latin America
    • Rest of World
      • Australia
      • Israel
      • Rest of World Countries

About Us:

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.


Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com 
Website: https://www.transparencymarketresearch.com 

Copyright © Transparency Market Research, Inc. All Rights reserved